Pricing Log in Create free account

Curis, Inc. (CRIS) vs Longeveron Inc. (LGVN)

Curis, Inc. and Longeveron Inc. are both Biotechnology companies. Curis, Inc. and Longeveron Inc. are of similar size ($5.7M and $5.5M). Curis, Inc. grew revenue faster over the last twelve months: −13.4% against −42.7%. Curis, Inc. has the higher net margin (0.00% vs −1,977.6%) and the higher return on invested capital (0.00% vs −4,549.0%). Across the 18 metrics below, Curis, Inc. leads on 12 and Longeveron Inc. on 6.

Valuation

Metric CRIS LGVN Biotechnology median
P/E n/m n/m 10.60
P/S 0.20 4.73 9.40
P/B 0.40 0.54 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.29 0.16 0.66
EV/Sales (0.27) (3.10) 9.02
Earnings yield (1,615.91%) (568.59%) (32.88%)
Free cash flow yield (1,649.45%) (371.04%) (23.13%)

Profitability

Metric CRIS LGVN Biotechnology median
Gross margin 99.52% 69.76% 68.51%
Operating margin 0.00% (1,992.84%) 0.00%
Net margin 0.00% (1,977.59%) 0.00%
Free cash flow margin 0.00% (1,755.69%) 0.00%
Return on equity 455.35% (203.61%) (51.96%)
Return on assets (87.76%) (145.64%) (46.06%)
Return on invested capital 0.00% (4,549.04%) 0.00%

Growth

Metric CRIS LGVN Biotechnology median
Revenue growth (TTM) (13.43%) (42.74%) 6.76%
EPS growth (last fiscal year) 91.57% 50.76% 29.88%
Revenue growth, 5-year CAGR (2.71%) (26.60%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRIS LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.49 2.63 4.97
Net debt to EBITDA 0.91 0.20 1.01

Dividend

Metric CRIS LGVN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRIS LGVN Biotechnology median
Market cap 5.67m 5.45m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack